1
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3
Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Tabarsi, P., Afzal, G., Eskandari, R. & Dastan, F. (2021). Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab. TANAFFOS (Respiration), 20(3), 188–191.
MLA
Tabarsi, P., Afzal, G., Eskandari, R., & Dastan, F. "Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab", TANAFFOS (Respiration), 20, 3, 2021, 188–191.
HARVARD
Tabarsi, P., Afzal, G., Eskandari, R., & Dastan, F. (2021). 'Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab', TANAFFOS (Respiration), 20(3), pp. 188–191.
CHICAGO
Tabarsi, P., Afzal, G., Eskandari, R. & Dastan, F., "Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab." TANAFFOS (Respiration), 20 3 (2021): 188–191,
VANCOUVER
Tabarsi P., Afzal G., Eskandari R., Dastan F. Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab. TANAFFOS (Respiration). 2021;20(3):188–191.
